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| INTRODUCTION
The field of radiation oncology has recently experienced a period of remarkable transformation of our technical capabilities. These technical and computational advancements have resulted in a tremendous improvement in our ability to precisely and accurately deliver radiation dose. However, this increased emphasis on technical capabilities may be inadvertently diverting attention and funding from scientific developments in other areas, even at a time when exciting new advances are occurring in cancer biology. Much of our recent technical development has been promoted and subsidized by the manufacturers of radiation oncology equipment. The question now becomes "who will encourage and subsidize the research needed to bring our recent biological advances to clinical fruition?" In a recent commentary which inspired this debate, Brown and Adler suggest that we "…are in a golden age of radiation and cancer biology" and that "…the industry's current focus on equipment development alone is undermining significant potential clinical advances in radiation oncology." 3 This is the subject of this month's 3DCRT debate.
Arguing for the proposition will be Drs. Leonard Kim 23 and genomic heterogeneity leading to potential differences in radioresistance 24, 25 are all other important areas of research that have the potential to drastically change radiation oncology. By investing research efforts into a more fundamental understanding of the biological basis of our targets, we can potentially improve patient outcomes and better utilize the equipment that is already developed.
In the US, government funding accounts for much of the funding for radiation oncology research. While there appears to be an emphasis on cancer biology amongst National Institutes of Health (NIH) funded grants, the total funding for a treatment modality (radiation) which is applied to two-thirds of all cancer patients is a mere 1.6% of NIH funding for cancer research. 26 Additionally, radiation oncology vendors should be motivated to invest in better understanding of cancer biology and specifically radiation biology, particularly in the setting of newer techniques such as SBRT and the implementation of increasing numbers of targeted agents. Not only could the efficacy of traditional radiation therapy be maximized with this approach, but novel indications for radiation as discussed above could greatly expand the use of radiotherapy and thus existing radiotherapy equipment. New inquiry should also include the effect of different radiation modalities on "normal tissues" affected by other pathologies such as seizure disorder, cardiovascular disease, and cardiac conductivity disorders to name only a few.
In conclusion, the field of radiation oncology must prioritize overall improvement in the quality of life and effectiveness of our therapies as motivation for innovation and not be swayed by industry or economic pressures. Equipment development has no doubt allowed Only a moderately increased radiation dose (6-9 Gy per fraction) was found to be necessary to stimulate immune activity, a dose already achievable by current clinical instrumentation. 43 Rather than further equipment development, the key problem and limitation for any clinical implementation of the ideas proposed in the study (as well as the gene-expression profiling study cited by our opponents (Ref.
[ 39 ]) is biological validation and understanding, without which further funding approval, clinical trial initiation, and adoption by clinicians will be limited.
In the end, the conclusion to which our opponents arrive is our own exact point. The innovations in our field most likely to make a significant impact on patient care and outcomes will only be achieved through better understanding the biology of our therapies and how radiation treatment may be best applied in a biological context. Investing in these areas -and not equipment developmentis exactly what our field should be doing starting no later than now.
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We agree with our colleagues' conclusion that radiation oncology must prioritize overall improvement in quality of life and effectiveness of therapies and that many gains are to be made by focusing on answering cancer and radiation biology questions. However, we want to highlight that equipment development IS part of innovation. Radiation oncology is a blend of biology, physics, and clinical care, and innovation in the field can only occur when equipment development occurs in parallel with understanding the biological basis behind the treatment. Often, equipment development outpaces our biological understanding as advances in technology have made engineering a device quicker than biological experimentation.
Advances in molecular techniques such as gene-expression profiling have been needed to further insights in general cancer biology.
These in turn have opened new areas of investigation for radiation biology. [44] [45] [46] While submillimeter accuracy may not be needed to treat all tumors, radiation therapy is used to treat a variety of tumor types that require different levels of accuracy and precision. One example of the huge clinical impact of submillimeter accuracy is during brain tumor radiation therapy, especially in children. Dose delivery in such cases is limited by the tolerance of normal tissues surrounding the target. 47, 48 Even with the current precision, nearly all children undergoing brain tumor radiation therapy develop a certain level of cognitive deficits long-term. The physical basis for the damage to the nontargeted brain cortex from MV x-rays or Co-60 gamma rays is the spatial distribution of the radiation they produce in the brain.
Specifically, the doses produced to the brain tissue located proximal and distal to the target are excessive. 49 Better accuracy translates to less normal brain cortex damage. Furthermore, without a reliable and safe way of accurately delivering radiation in the clinic, even the most detailed radiobiologic understanding would have limited translation into real patient care.
As for the concern regarding funding, we are in complete agreement that not enough NIH research dollars are allocated to the study of basic radiobiology and radiation oncology in general. However, until this can be changed, any additional funding to help move our field forward should be not be discounted. There are examples of equipment development based on evidence where private developers work in conjunction with the NIH to generate relevant clinical data. A good example is the emerging data for rectal sparing in prostate cancer. We know risk of rectal toxicity depends on the volume of the rectum that receives a high-radiation dose. In a large prospective series, the percentage of rectum receiving > 70 Gy (V70) correlated with the occurrence of chronic rectal toxicity. 50 Based on this information, in vitro work was supported by NIH grants and cadaveric studies funded by an equipment developing company to analyze risks, benefits, and dosimetric effects of prostate-rectum separation using polyethylene-glycol (PEG)-based hydrogels. 51 Evaluation in a prospective multicenter randomized controlled trial showed a significant reduction in late (3-15 months) rectal toxicity severity. 52 Finally, our colleagues make the argument that we may have plateaued on accuracy due to CTV accounting for uncertain margins.
Thus far SBRT ablative doses are delivered without a CTV, therefore, little to no room for uncertainty. As we head toward immune modulation in combination with radiation therapy and tumor microenvironment modulation with radiation, as predicted by our colleagues, we will likely need even more accuracy in radiation treatment delivery.
Overall, in order to deliver innovative radiation oncology treatments in the clinic, we will continue to require equipment development. Therefore, while it will be essential to answer cancer and radiation biology questions, equipment development will continue to be an integral part innovation in radiation oncology.
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